AKT1 and renal cell adenocarcinoma: A classical chemotherapeutic agent such as paclitaxel, a microtubule formation inhibitor, was tested on RCC cell lines, and low doses show increased production of ceramide, derived from sphingomyelin hydrolysis, which impairs Akt phosphorylation.